Physician profile
Jason C Stepp
NPI 1124226311
$1,179.83
in general payments reported to CMS, 2019-2025
20 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.56 · 2022: $138 · 2023: $196 · 2024: $544 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.02 |
| Education | $319.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $321.68 | 2024-2025 | |
| Daiichi Sankyo INC. | $191.16 | 2021-2024 | Injectafer, Vanflyta |
| Eisai INC. | $84.84 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $77.55 | 2022-2023 | Libtayo |
| Genzyme Corporation | $71.31 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $54.58 | 2024 | |
| Pfizer INC. | $49.32 | 2025 | |
| Myovant Sciences INC. | $47.86 | 2021-2022 | |
| Incyte Corporation | $41.71 | 2024 | Pemazyre, Monjuvi, Jakafi |
| Celgene Corporation | $37.84 | 2023-2024 | |
| Janssen Biotech, INC. | $26.64 | 2023 | Darzalex |
| Abbvie INC. | $26.03 | 2025 | |
| Acrotech Biopharma INC. | $25.90 | 2021 | |
| Tempus Ai, INC | $24.19 | 2024 | Xt Cdx |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $20.38 | 2024 | Orserdu |
| Genentech USA, INC. | $19.53 | 2024 | Venclexta |
| Seagen INC. | $15.35 | 2023 | Adcetris |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.